S. 124, Preserve Access to Affordable Generics Act

S. 124, Preserve Access to Affordable Generics Act

If signed into law, S. 124 will prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.

Sen. Amy Klobuchar (MN) introduced S. 124 on January 12, 2017. It has been referred to Committee on the Judiciary.

Learn more about S. 124 »

Print Friendly

Close